Published in Int J Cardiol on July 18, 2013
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Peripheral arterial disease is prevalent but underdiagnosed and undertreated in the primary care setting in central Greece. Angiology (2012) 1.93
Time for new indications for statins? Med Sci Monit (2009) 1.87
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Endovascular stent-graft repair of major abdominal arteriovenous fistula: a systematic review. J Endovasc Ther (2009) 1.46
Outcome after endovascular stent graft repair of aortoenteric fistula: A systematic review. J Vasc Surg (2008) 1.46
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Blood velocity pulse quantification in the human conjunctival pre-capillary arterioles. Microvasc Res (2010) 1.09
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Asymptomatic cerebral lesions after carotid artery stenting may not predict future cerebrovascular events but may be associated with cognitive impairment. JACC Cardiovasc Interv (2013) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
Confidentiality governing surgical research practice. World J Surg (2005) 1.07
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
Metformin and cancer: licence to heal? Expert Opin Investig Drugs (2010) 1.01
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother (2008) 1.00
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol (2006) 1.00
Metabolic syndrome and renal disease. Int J Cardiol (2012) 0.99
The role of serotonin in tumour growth (review). Oncol Rep (2005) 0.99
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99
Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem (2009) 0.99
The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit (2009) 0.99
Abdominal aortic aneurysm and abdominal wall hernia as manifestations of a connective tissue disorder. J Vasc Surg (2011) 0.99
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol (2006) 0.99
The meaning of hypokalemia in heart failure. Int J Cardiol (2011) 0.98
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol (2013) 0.98
The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int (2006) 0.98
Coagulation, platelets, and acute pancreatitis. Pancreas (2007) 0.98
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol (2011) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model. In Vivo (2012) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
Apolipoprotein E knockout models. Curr Pharm Des (2008) 0.96
Influence of smoking on predictors of vascular disease. Angiology (2003) 0.96
Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol (2009) 0.95
A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res (2002) 0.95
Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology (2007) 0.95
Takotsubo cardiomyopathy--the current state of knowledge. Int J Cardiol (2010) 0.95
Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets (2009) 0.95
Erectile dysfunction: a need for greater awareness. J R Soc Promot Health (2004) 0.95
Statin discontinuation: an underestimated risk? Curr Med Res Opin (2008) 0.95
Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis (2008) 0.94